Literature DB >> 23109424

Defective autophagy and mTORC1 signaling in myotubularin null mice.

Kristina M Fetalvero1, Yenyen Yu, Margaret Goetschkes, Guiqing Liang, Reginald A Valdez, Ty Gould, Ellen Triantafellow, Sebastian Bergling, Joseph Loureiro, John Eash, Victor Lin, Jeffrey A Porter, Peter M Finan, Kenneth Walsh, Yi Yang, Xiaohong Mao, Leon O Murphy.   

Abstract

Autophagy is a vesicular trafficking pathway that regulates the degradation of aggregated proteins and damaged organelles. Initiation of autophagy requires several multiprotein signaling complexes, such as the ULK1 kinase complex and the Vps34 lipid kinase complex, which generates phosphatidylinositol 3-phosphate [PtdIns(3)P] on the forming autophagosomal membrane. Alterations in autophagy have been reported for various diseases, including myopathies. Here we show that skeletal muscle autophagy is compromised in mice deficient in the X-linked myotubular myopathy (XLMTM)-associated PtdIns(3)P phosphatase myotubularin (MTM1). Mtm1-deficient muscle displays several cellular abnormalities, including a profound increase in ubiquitin aggregates and abnormal mitochondria. Further, we show that Mtm1 deficiency is accompanied by activation of mTORC1 signaling, which persists even following starvation. In vivo pharmacological inhibition of mTOR is sufficient to normalize aberrant autophagy and improve muscle phenotypes in Mtm1 null mice. These results suggest that aberrant mTORC1 signaling and impaired autophagy are consequences of the loss of Mtm1 and may play a primary role in disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23109424      PMCID: PMC3536306          DOI: 10.1128/MCB.01075-12

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  61 in total

1.  ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy.

Authors:  Ian G Ganley; Du H Lam; Junru Wang; Xiaojun Ding; She Chen; Xuejun Jiang
Journal:  J Biol Chem       Date:  2009-03-03       Impact factor: 5.157

2.  Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids.

Authors:  Yasemin Sancak; Liron Bar-Peled; Roberto Zoncu; Andrew L Markhard; Shigeyuki Nada; David M Sabatini
Journal:  Cell       Date:  2010-04-08       Impact factor: 41.582

3.  AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.

Authors:  Christine M Chresta; Barry R Davies; Ian Hickson; Tom Harding; Sabina Cosulich; Susan E Critchlow; John P Vincent; Rebecca Ellston; Darren Jones; Patrizia Sini; Dominic James; Zoe Howard; Phillippa Dudley; Gareth Hughes; Lisa Smith; Sharon Maguire; Marc Hummersone; Karine Malagu; Keith Menear; Richard Jenkins; Matt Jacobsen; Graeme C M Smith; Sylvie Guichard; Martin Pass
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

4.  The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1.

Authors:  Masaaki Komatsu; Hirofumi Kurokawa; Satoshi Waguri; Keiko Taguchi; Akira Kobayashi; Yoshinobu Ichimura; Yu-Shin Sou; Izumi Ueno; Ayako Sakamoto; Kit I Tong; Mihee Kim; Yasumasa Nishito; Shun-ichiro Iemura; Tohru Natsume; Takashi Ueno; Eiki Kominami; Hozumi Motohashi; Keiji Tanaka; Masayuki Yamamoto
Journal:  Nat Cell Biol       Date:  2010-02-21       Impact factor: 28.824

5.  Zebrafish MTMR14 is required for excitation-contraction coupling, developmental motor function and the regulation of autophagy.

Authors:  J J Dowling; S E Low; A S Busta; E L Feldman
Journal:  Hum Mol Genet       Date:  2010-04-16       Impact factor: 6.150

6.  Mitochondrial fission and remodelling contributes to muscle atrophy.

Authors:  Vanina Romanello; Eleonora Guadagnin; Ligia Gomes; Ira Roder; Claudia Sandri; Yvonne Petersen; Giulia Milan; Eva Masiero; Paola Del Piccolo; Marc Foretz; Luca Scorrano; Rudiger Rudolf; Marco Sandri
Journal:  EMBO J       Date:  2010-04-16       Impact factor: 11.598

7.  Control of autophagy initiation by phosphoinositide 3-phosphatase Jumpy.

Authors:  Isabelle Vergne; Esteban Roberts; Rasha A Elmaoued; Valérie Tosch; Mónica A Delgado; Tassula Proikas-Cezanne; Jocelyn Laporte; Vojo Deretic
Journal:  EMBO J       Date:  2009-07-09       Impact factor: 11.598

8.  Modulation of local PtdIns3P levels by the PI phosphatase MTMR3 regulates constitutive autophagy.

Authors:  Naoko Taguchi-Atarashi; Maho Hamasaki; Kohichi Matsunaga; Hiroko Omori; Nicholas T Ktistakis; Tamotsu Yoshimori; Takeshi Noda
Journal:  Traffic       Date:  2010-01-06       Impact factor: 6.215

9.  Mitochondrial fusion is required for mtDNA stability in skeletal muscle and tolerance of mtDNA mutations.

Authors:  Hsiuchen Chen; Marc Vermulst; Yun E Wang; Anne Chomyn; Tomas A Prolla; J Michael McCaffery; David C Chan
Journal:  Cell       Date:  2010-04-16       Impact factor: 41.582

Review 10.  Coordination of membrane events during autophagy by multiple class III PI3-kinase complexes.

Authors:  Anne Simonsen; Sharon A Tooze
Journal:  J Cell Biol       Date:  2009-09-21       Impact factor: 10.539

View more
  40 in total

1.  AUTEN-67, an autophagy-enhancing drug candidate with potent antiaging and neuroprotective effects.

Authors:  Diána Papp; Tibor Kovács; Viktor Billes; Máté Varga; Anna Tarnóci; László Hackler; László G Puskás; Hanna Liliom; Krisztián Tárnok; Katalin Schlett; Adrienn Borsy; Zsolt Pádár; Attila L Kovács; Krisztina Hegedűs; Gábor Juhász; Marcell Komlós; Attila Erdős; Balázs Gulyás; Tibor Vellai
Journal:  Autophagy       Date:  2016       Impact factor: 16.016

2.  Reducing dynamin 2 expression rescues X-linked centronuclear myopathy.

Authors:  Belinda S Cowling; Thierry Chevremont; Ivana Prokic; Christine Kretz; Arnaud Ferry; Catherine Coirault; Olga Koutsopoulos; Vincent Laugel; Norma B Romero; Jocelyn Laporte
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

3.  In vivo imaging of skeletal muscle in mice highlights muscle defects in a model of myotubular myopathy.

Authors:  Luc Mercier; Johann Böhm; Nina Fekonja; Guillaume Allio; Yves Lutz; Marc Koch; Jacky G Goetz; Jocelyn Laporte
Journal:  Intravital       Date:  2016-04-06

4.  Single Intramuscular Injection of AAV-shRNA Reduces DNM2 and Prevents Myotubular Myopathy in Mice.

Authors:  Hichem Tasfaout; Valentina M Lionello; Christine Kretz; Pascale Koebel; Nadia Messaddeq; Deborah Bitz; Jocelyn Laporte; Belinda S Cowling
Journal:  Mol Ther       Date:  2018-02-14       Impact factor: 11.454

Review 5.  Pathophysiological concepts in the congenital myopathies: blurring the boundaries, sharpening the focus.

Authors:  Gianina Ravenscroft; Nigel G Laing; Carsten G Bönnemann
Journal:  Brain       Date:  2014-12-31       Impact factor: 13.501

6.  PIK3C2B inhibition improves function and prolongs survival in myotubular myopathy animal models.

Authors:  Nesrin Sabha; Jonathan R Volpatti; Hernan Gonorazky; Aaron Reifler; Ann E Davidson; Xingli Li; Nadine M Eltayeb; Claudia Dall'Armi; Gilbert Di Paolo; Susan V Brooks; Ana Buj-Bello; Eva L Feldman; James J Dowling
Journal:  J Clin Invest       Date:  2016-08-22       Impact factor: 14.808

Review 7.  Triadopathies: an emerging class of skeletal muscle diseases.

Authors:  James J Dowling; Michael W Lawlor; Robert T Dirksen
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

Review 8.  Phosphatidylinositol 3-phosphates-at the interface between cell signalling and membrane traffic.

Authors:  Andrea L Marat; Volker Haucke
Journal:  EMBO J       Date:  2016-02-17       Impact factor: 11.598

Review 9.  Skeletal muscle autophagy: a new metabolic regulator.

Authors:  Brian A Neel; Yuxi Lin; Jeffrey E Pessin
Journal:  Trends Endocrinol Metab       Date:  2013-10-29       Impact factor: 12.015

10.  AAV-Mediated Gene Transfer Restores a Normal Muscle Transcriptome in a Canine Model of X-Linked Myotubular Myopathy.

Authors:  Jean-Baptiste Dupont; Jianjun Guo; Edith Renaud-Gabardos; Karine Poulard; Virginie Latournerie; Michael W Lawlor; Robert W Grange; John T Gray; Ana Buj-Bello; Martin K Childers; David L Mack
Journal:  Mol Ther       Date:  2019-11-11       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.